IN8bio
Phase 2IN8bio uses genetically modified gamma-delta (γδ) T cells to address the challenges with cold, low mutation cancers
Founded
2016
Focus
BiologicsSmall Molecules
About
IN8bio uses genetically modified gamma-delta (γδ) T cells to address the challenges with cold, low mutation cancers
Funding History
3Total raised: $80M
IPO$40MUndisclosedAug 13, 2021
Series B$25MArkin Bio VenturesFeb 15, 2020
Series A$15MArkin Bio VenturesJun 15, 2018
Company Info
TypePrivate
Founded2016
LocationNew York, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile